Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies.
Amy C ShermanJennifer L CrombieChi-An ChengMichaël DesjardinsGuohai ZhouOmolola OmetoruwaRebecca RooksYasmeen SenussiMikaela McDonoughLiliana I GuerreroJohn KupelianSimon Doss-GollinKinga K SmolenSimon D van HarenPhilippe ArmandOfer LevyDavid R WaltLindsey R BadenNicolas C IssaPublished in: Open forum infectious diseases (2022)
A 3-dose primary mRNA series enhanced anti-S IgG responses to titers equivalent to healthy adults in patients with lymphoid malignancies who were seropositive after the first 2 doses and seroconverted 17.1% who were seronegative after the first 2 doses. T-cell responses were present, raising the possibility that the vaccines may confer some cell-based protection even if not measurable by anti-S IgG.